William Novotny - Concepedia

Author

William Novotny

Also Known As

W F Novotny, W Novotny, W. F. Novotny, W. Novotny, W.F. Novotny, WILLIAM NOVOTNY, William F Novotny, William F. Novotny, William Novotny

176

Publications

30.5K

Citations

H-Index

100

Concepts

All Affiliations

Duke University BeiGene (China)Sarah Cannon Peking University Chinese Academy of Medical Sciences & Peking Union Medical College

About

William Novotny is an author at Duke University specializing in medicine, pharmacology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	23	35	5.1K
2	Health Sciences	6	6	333
3	Natural Sciences	2	2	71
4	Public Health	1	1	30
5	Allergy	1	1	82

William Novotny

Publications

26.2K

Citations

H-Index

Page 1

	Year	Citations
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer Herbert I. Hurwitz, Louis Fehrenbacher, William Novotny, New England Journal of Medicine	2004	10.9K
Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer David H. Johnson, Louis Fehrenbacher, William Novotny, Journal of Clinical Oncology	2004	1.9K
Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of <i>HER2</i>-Overexpressing Metastatic Breast Cancer Charles L. Vogel, Melody Cobleigh, Debu Tripathy, Journal of Clinical Oncology Breast OncologySingle AgentMedicineCancer ManagementPharmacology	2002	1.8K
Phase II, Randomized Trial Comparing Bevacizumab Plus Fluorouracil (FU)/Leucovorin (LV) With FU/LV Alone in Patients With Metastatic Colorectal Cancer Fairooz F. Kabbinavar, Herbert I. Hurwitz, Louis Fehrenbacher, Journal of Clinical Oncology	2002	1.7K
Addition of Bevacizumab to Bolus Fluorouracil and Leucovorin in First-Line Metastatic Colorectal Cancer: Results of a Randomized Phase II Trial Fairooz F. Kabbinavar, Joseph J. Schulz, Michael McCleod, Journal of Clinical Oncology	2005	932
High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants Pedram Razavi, Bob T. Li, David N. Brown, Nature Medicine Dna SequencingSequencingHigh-intensity SequencingSingle Cell SequencingCell-free Dna Variants	2019	718
Bevacizumab in Combination With Fluorouracil and Leucovorin: An Active Regimen for First-Line Metastatic Colorectal Cancer Herbert I. Hurwitz, Louis Fehrenbacher, John D. Hainsworth, Journal of Clinical Oncology	2005	683
Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab Frank A. Scappaticci, Louis Fehrenbacher, Thomas H. Cartwright, Journal of Surgical Oncology	2005	525
Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor Thomas Girard, Louise A. Warren, William Novotny, Nature ThrombosisLipoprotein-associated Coagulation InhibitorBiochemistryMedicineKunitz-type Inhibitory Domains	1989	478
Phase I Dose-Escalation Study of Recombinant Human Apo2L/TRAIL, a Dual Proapoptotic Receptor Agonist, in Patients With Advanced Cancer Roy S. Herbst, S. Gail Eckhardt, Razelle Kurzrock, Journal of Clinical Oncology	2010	437

Page 1